MC
ANIK icon

Miles Capital’s Anika Therapeutics ANIK Stock Holding History

Miles Capital’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,768
Closed -$237K – 184
2018
Q1 		$237K Buy
4,768
+179
+4% +$10.1K 0.13% 170
2017
Q4 		$247K Sell
4,589
-27
-0.6% -$1.49K 0.14% 130
2017
Q3 		$268K Sell
4,616
-79
-2% -$4.13K 0.15% 112
2017
Q2 		$232K Buy
+4,695
New +$216K 0.12% 157

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Miles Capital's ANIK Position: Q2 2018 in Review

Miles Capital sold out of Anika Therapeutics (ANIK) in Q2 2018, closing a stake of 4,768 shares — an estimated $237K sold.

Miles Capital first reported a position in ANIK in Q2 2017 and held it in 4 quarters. The position peaked at $268K in Q3 2017. 170 funds tracked by Wall St. Rank hold ANIK as of Q2 2018.

  • Miles Capital reported no remaining Anika Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Miles Capital sold 4,768 Anika Therapeutics shares in Q2 2018, an estimated $237K.
  • Miles Capital first reported a position in Anika Therapeutics in Q2 2017 and held it in 4 quarters.
  • Miles Capital's Anika Therapeutics position peaked at $268K in Q3 2017.
  • 170 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2018.

Based on Miles Capital's 13F filing for Q2 2018, filed 14 Aug 2018.